DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus

Key Takeaways DNLI reported a Q4 loss of $0.73 per share, beating estimates but wider year over year.Denali Therapeutics' BLA for tividenofusp alfa faces April 5, 2026, FDA action date after major amendment.DNLI ended 2025 with $966.2M in cash as it advances DNL126 and other partnered programs.Denali Therapeutics (DNLI) reported a fourth-quarter 2025 loss of 73 cents per share, narrower than the Zacks Consensus Estimate of a loss of 75 cents. The company reported a loss of 67 cents in the year-ago quarter.T ...